ConductScience.org, home

Paper498145

Anticancer activity of cis-dichlorodiammineplatinum(II) and some relevant chemistry.

Rosenberg B. Cancer Treat Rep, 1979. Cited by 118 papers, by iCite.

Cite this record

ConductScience Library. Anticancer activity of cis-dichlorodiammineplatinum(II) and some relevant chemistry. Papers, record 498145. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/498145

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Anticancer activity of cis-dichlorodiammineplatinum(II) and some relevant chemistry.
PubMed
Journal
Cancer Treat Rep
PubMed
Year
1979
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
118
iCite
Relative citation ratio, by iCite
4.05
iCite
Revised in PubMed
2013-11-21
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rosenberg BB

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic AgentsMajor topic
CisplatinMajor topic
Animals
DNA
Guanine
Mice
Neoplasms, Experimental
Stereoisomerism
Structure-Activity Relationship
Water

Source PubMed

Download CSV of topics

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 118 citations.

PMIDTitleJournalYearIn PapersSource
39106540Repair of genomic interstrand crosslinks.DNA Repair (Amst)2024https://conductscience.org/library/papers/39106540PubMed
34097405Internal and External Influences on Stability and Ligand Exchange Reactions in Bromido[3-ethyl-4-aryl-5-(2-methoxypyridin-5-yl)-1-propyl-1,3-dihydro-2H-imidazol-2-ylidene]gold(I) Complexes.Inorg Chem2021https://conductscience.org/library/papers/34097405PubMed
33622870Combination Cancer Therapy of a Del1 Fragment and Cisplatin Enhanced Therapeutic Efficiency In Vivo.In Vivo2021https://conductscience.org/library/papers/33622870PubMed
31458267Metallothionein: An Aggressive Scavenger-The Metabolism of Rhodium(II) Tetraacetate (Rh2(CH3CO2)4).ACS Omega2018https://conductscience.org/library/papers/31458267PubMed
27079977Insights into RNA binding by the anticancer drug cisplatin from the crystal structure of cisplatin-modified ribosome.Nucleic Acids Res2016https://conductscience.org/library/papers/27079977PubMed
21931655Bioluminescence-based high-throughput screen identifies pharmacological agents that target neurotransmitter signaling in small cell lung carcinoma.PLoS One2011https://conductscience.org/library/papers/21931655PubMed
16600465Copper(II) and manganese(III) complexes of N'-[(2-hydroxy phenyl) carbonothioyl] pyridine-2-carbohydrazide: novel therapeutic agents for cancer.Biochimie2006https://conductscience.org/library/papers/16600465PubMed
12488594Antitumorigenic Evaluation of Thalidomide Alone and in Combination with Cisplatin in DBA2/J Mice.J Biomed Biotechnol2002https://conductscience.org/library/papers/12488594PubMed
8630273Hypotonic intraperitoneal cisplatin chemotherapy for peritoneal carcinomatosis in mice.Br J Cancer1996https://conductscience.org/library/papers/8630273PubMed
7242687Intracellular distribution of titanium after treatment with the antitumor agent titanocene dichloride: on electron energy loss spectroscopic study.Naturwissenschaften1981https://conductscience.org/library/papers/7242687PubMed
6891949"Two route infusion chemotherapy" using cis-Diamminedichloroplatinum (II) and its antidote, sodium thiosulfate, for metastatic liver tumors in rats.Jpn J Surg1982https://conductscience.org/library/papers/6891949PubMed
6824567Enhancement of the DNA cross-linking activity of melphalan by misonidazole in vivo.Br J Cancer1983https://conductscience.org/library/papers/6824567PubMed
3910609Comparative cytotoxicity between cisplatin and second generation platinum analogs.Invest New Drugs1985https://conductscience.org/library/papers/3910609PubMed
2729945Protective effect of piperacillin against the nephrotoxicity of cisplatin in rats.Antimicrob Agents Chemother1989https://conductscience.org/library/papers/2729945PubMed
2660897The effect of reduced osmolarity on platinum drug toxicity.Br J Cancer1989https://conductscience.org/library/papers/2660897PubMed
2381427Differential effects of cisplatin on mouse hepatic and renal mitochondrial DNA.Mol Cell Biochem1990https://conductscience.org/library/papers/2381427PubMed
2347043Evidence for lack of mitochondrial DNA repair following cis-dichlorodiammineplatinum treatment.Cancer Chemother Pharmacol1990https://conductscience.org/library/papers/2347043PubMed
2178792A strategy for the development of two clinically active cisplatin analogs: CBDCA and CHIP.Cancer Chemother Pharmacol1990https://conductscience.org/library/papers/2178792PubMed
1568289Modification of the physicochemical and pharmacological properties of anticancer platinum compounds by commercial 5-fluorouracil formulations: a comparative study using cisplatin and carboplatin.Cancer Chemother Pharmacol1992https://conductscience.org/library/papers/1568289PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/498145

GET https://conductscience.org/api/papers/v1/498145/authors